These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 36435704)

  • 1. Economic impact of vaccine safety incident in Ukraine: The economic case for safety system investment.
    Budigan Ni H; de Broucker G; Patenaude BN; Dudley MZ; Hampton LM; Salmon DA
    Vaccine; 2023 Jan; 41(1):219-225. PubMed ID: 36435704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Public Health and Economic Consequences of Vaccine Hesitancy for Measles in the United States.
    Lo NC; Hotez PJ
    JAMA Pediatr; 2017 Sep; 171(9):887-892. PubMed ID: 28738137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measles: a new danger for Ukraine's children! The need for an effective and timely vaccination prevention campaign for an insidious disease that comes from afar.
    Orsini D; Martini M
    J Prev Med Hyg; 2023 Jun; 64(2):E204-E208. PubMed ID: 37654850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccination coverage rates and the incidence of vaccine preventable diseases among children in sumy region of Ukraine.
    Smiianov VA; Zaitseva HS; Kurganskaya VA; Dyachenko AG; Zbarazhskyi VP; Smiianov YV; Pilipec OA
    Wiad Lek; 2019; 72(2):255-260. PubMed ID: 30903783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modeling the Transmission of Measles and Rubella to Support Global Management Policy Analyses and Eradication Investment Cases.
    Thompson KM; Badizadegan ND
    Risk Anal; 2017 Jun; 37(6):1109-1131. PubMed ID: 28561947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic analysis of measles elimination program in the Republic of Korea, 2001: a cost benefit analysis study.
    Bae GR; Choe YJ; Go UY; Kim YI; Lee JK
    Vaccine; 2013 May; 31(24):2661-6. PubMed ID: 23602654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The societal cost of vaccine refusal: A modelling study using measles vaccination as a case study.
    Olivera Mesa D; Winskill P; Ghani AC; Hauck K
    Vaccine; 2023 Jun; 41(28):4129-4137. PubMed ID: 37263873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measles Resurgence in Europe: Migrants and Travellers are not the Main Drivers.
    Leong WY; Wilder-Smith AB
    J Epidemiol Glob Health; 2019 Dec; 9(4):294-299. PubMed ID: 31854172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measles, mumps, rubella prevention: how can we do better?
    Kauffmann F; Heffernan C; Meurice F; Ota MOC; Vetter V; Casabona G
    Expert Rev Vaccines; 2021 Jul; 20(7):811-826. PubMed ID: 34096442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse events following immunization: Findings from 2017/2018 measles vaccination campaign, Nigeria AEFI reporting in 2017/2018 measles vaccination campaign.
    Gbenewei E; Nomhwange T; Taiwo L; Ayodeji I; Yusuf K; Jean Baptiste AE; Nsubuga P; Braka F; Oteri J; Shuaib F
    Vaccine; 2021 Nov; 39 Suppl 3():C82-C88. PubMed ID: 33714655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health and economic costs of an import-initiated measles outbreak in an international border area of Yunnan Province.
    Zhou R; Li L; Yuan S; Yin J; Li Q; Guo L; Li M; Zhao Z; Song Z
    Hum Vaccin Immunother; 2021 May; 17(5):1347-1352. PubMed ID: 32991225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measles vaccination of special risk groups.
    Papaevangelou V
    Hum Vaccin Immunother; 2021 Dec; 17(12):5384-5387. PubMed ID: 34788199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measles outbreak in the Ukraine, 2005-2006.
    Spika JS; Aidyralieva C; Mukharskaya L; Kostyuchenko NN; Mulders M; Lipskaya G; Emiroglu N
    Euro Surveill; 2006 Mar; 11(3):E060309.1. PubMed ID: 16804226
    [No Abstract]   [Full Text] [Related]  

  • 14. Lessons from measles vaccination in developing countries.
    Hall AJ; Cutts FT
    BMJ; 1993 Nov; 307(6915):1294-5. PubMed ID: 8257878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The economic cost of measles: Healthcare, public health and societal costs of the 2012-13 outbreak in Merseyside, UK.
    Ghebrehewet S; Thorrington D; Farmer S; Kearney J; Blissett D; McLeod H; Keenan A
    Vaccine; 2016 Apr; 34(15):1823-31. PubMed ID: 26944712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measles outbreaks: they are preventable but keep progressing dangerously.
    Smiianov VA; Kurhanska VA; Smiianova OI
    Wiad Lek; 2019; 72(11 cz 1):2145-2148. PubMed ID: 31860862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of economic costs of a measles outbreak and outbreak response activities in Keffa Zone, Ethiopia.
    Wallace AS; Masresha BG; Grant G; Goodson JL; Birhane H; Abraham M; Endailalu TB; Letamo Y; Petu A; Vijayaraghavan M
    Vaccine; 2014 Jul; 32(35):4505-4514. PubMed ID: 24951866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Societal Costs of a Measles Outbreak.
    Pike J; Melnick A; Gastañaduy PA; Kay M; Harbison J; Leidner AJ; Rice S; Asato K; Schwartz L; DeBolt C
    Pediatrics; 2021 Apr; 147(4):. PubMed ID: 33712549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolving measles status and immunization policy development in six European countries.
    Vojtek I; Larson H; Plotkin S; Van Damme P
    Hum Vaccin Immunother; 2022 Dec; 18(1):2031776. PubMed ID: 35180372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measles epidemiology and outbreak response immunization in a rural community in Peru.
    Sniadack DH; Moscoso B; Aguilar R; Heath J; Bellini W; Chiu MC
    Bull World Health Organ; 1999; 77(7):545-52. PubMed ID: 10444877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.